Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.54 |
| ▸ | OGA | O60502 | 1/20 | 0.53 |
| ▸ | HEXA | P06865 | 1/20 | 0.53 |
| ▸ | HEXB | P07686 | 1/20 | 0.53 |
| ▸ | GLS | O94925 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805142 | 0.84 | OGA (0.70) | ACHEOGAHEXAHEXBGLS | |
| SCHEMBL7973833 | 0.82 | OGA (0.68) | ACHEOGAHEXAHEXBGLS | |
| SCHEMBL21852741 | 0.80 | NPSR1 (0.56) | ACHEOGAHEXAHEXB | |
| SCHEMBL9827604 | 0.79 | ACHE (0.69) | ACHESIRT1 | |
| SCHEMBL30185439 | 0.79 | GLS (0.57) | GLS | |
| SCHEMBL1042197 | 0.79 | GLS (0.57) | GLS | |
| SCHEMBL1210939 | 0.78 | OGA (0.57) | ACHEOGAHEXAHEXBGLS | |
| SCHEMBL7476248 | 0.78 | SIRT1 (0.66) | ACHEOGAHEXAHEXBSIRT1 | |
| SCHEMBL11765817 | 0.77 | OGA (0.53) | ACHEOGAHEXAHEXBGLS | |
| SCHEMBL6699936 | 0.77 | GLS (0.71) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | CITY OF HOPE | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | TXN, TXN2, TXNRD3 | ACHE 4220/4885OGA 1132/4885HEXA 3091/4885 |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | TXN, TXN2, TXNRD3 | ACHE 4220/4885OGA 1132/4885HEXA 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.